DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Receives Consensus Recommendation of “Hold” from Analysts

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) has been assigned a consensus recommendation of “Hold” from the fifteen analysts that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, ten have given a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $14.4167.

XRAY has been the subject of several research reports. Barrington Research lifted their price target on DENTSPLY SIRONA from $14.00 to $17.00 and gave the company an “outperform” rating in a report on Monday, March 2nd. Barclays initiated coverage on shares of DENTSPLY SIRONA in a research report on Monday, December 8th. They set an “underweight” rating and a $12.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of DENTSPLY SIRONA in a research note on Wednesday, January 21st. UBS Group decreased their target price on shares of DENTSPLY SIRONA from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Finally, Robert W. Baird increased their price target on shares of DENTSPLY SIRONA from $12.00 to $14.00 and gave the stock a “neutral” rating in a research note on Friday, February 27th.

DENTSPLY SIRONA Stock Performance

NASDAQ XRAY opened at $11.63 on Friday. The company has a current ratio of 1.51, a quick ratio of 1.03 and a debt-to-equity ratio of 1.50. DENTSPLY SIRONA has a 1-year low of $9.85 and a 1-year high of $17.18. The firm’s fifty day simple moving average is $12.47 and its 200-day simple moving average is $12.14. The company has a market capitalization of $2.32 billion, a PE ratio of -3.88, a price-to-earnings-growth ratio of 1.37 and a beta of 0.99.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. The firm had revenue of $961.00 million during the quarter, compared to analysts’ expectations of $926.40 million. During the same quarter last year, the firm earned $0.26 EPS. The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, sell-side analysts anticipate that DENTSPLY SIRONA will post 1.84 earnings per share for the current fiscal year.

Insider Buying and Selling at DENTSPLY SIRONA

In other DENTSPLY SIRONA news, Director James D. Forbes bought 5,000 shares of the stock in a transaction on Monday, March 9th. The shares were purchased at an average cost of $12.48 per share, with a total value of $62,400.00. Following the completion of the transaction, the director directly owned 10,000 shares of the company’s stock, valued at $124,800. This represents a 100.00% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Gregory T. Lucier bought 27,555 shares of the business’s stock in a transaction on Monday, March 2nd. The shares were bought at an average price of $14.24 per share, for a total transaction of $392,383.20. Following the completion of the acquisition, the director owned 27,555 shares of the company’s stock, valued at approximately $392,383.20. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 70,000 shares of company stock worth $956,437 over the last three months. Company insiders own 0.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in XRAY. Daiwa Securities Group Inc. lifted its holdings in DENTSPLY SIRONA by 2.9% in the 4th quarter. Daiwa Securities Group Inc. now owns 26,814 shares of the medical instruments supplier’s stock worth $306,000 after purchasing an additional 767 shares during the last quarter. Arizona State Retirement System grew its holdings in DENTSPLY SIRONA by 1.4% during the third quarter. Arizona State Retirement System now owns 58,952 shares of the medical instruments supplier’s stock valued at $748,000 after purchasing an additional 807 shares during the last quarter. True Wealth Design LLC raised its position in shares of DENTSPLY SIRONA by 49.7% in the third quarter. True Wealth Design LLC now owns 3,557 shares of the medical instruments supplier’s stock valued at $45,000 after purchasing an additional 1,181 shares during the period. Sivia Capital Partners LLC raised its position in shares of DENTSPLY SIRONA by 5.3% in the third quarter. Sivia Capital Partners LLC now owns 25,774 shares of the medical instruments supplier’s stock valued at $327,000 after purchasing an additional 1,293 shares during the period. Finally, Empowered Funds LLC lifted its stake in shares of DENTSPLY SIRONA by 8.8% in the first quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock worth $244,000 after buying an additional 1,320 shares during the last quarter. Institutional investors and hedge funds own 95.70% of the company’s stock.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.